Glycated proteins in diabetes

Clinics in Laboratory Medicine

Volumn 21, Issue 1, 2001, Pages 53-78

  Beisswenger, P J ^a   Szwergold, B S ^a   Yeo, K T ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ADVANCED GLYCATION END PRODUCT; AMINE; REDUCING AGENT; SUGAR ACID;

AGING; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIAGNOSTIC VALUE; HUMAN; PATHOGENESIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN GLYCOSYLATION; REVIEW;

BLOOD PROTEINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLYCOPROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA;

EID: 0035066126     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. The Maillard reaction in foods and medicine
2. N-epsilon (carboxethyl) lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens protein
3. Fructosamine: Structure, analysis, and clinical usefulness
4. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
5. Biguanides and NIDDM
6. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management
7. Use of protein-based standards in automated colorimetric determinations of fructosamine in serum
8. Fructosamine Test-Plus: A modified fructosamine assay evaluated
9. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
10. Nonenzymatic glucosylation of lysine residues in albumin
11. Glycosylated serum proteins and glycosylated hemoglobin in the assessment of glycemic control in insulin-dependent and noninsulin-dependent diabetes mellitus
12. Metformin reduces systemic methylglyoxal levels in type 2 diabetes
13. Acetol production is increased in early diabetic nephropathy
14. The role of 3-deoxyglucosone and the activity of its degradative pathways in the etiology of diabetic microvascular disease
15. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
16. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy
17. Variable methylglyoxal production from hyperglycemia
18. The effect of hyperglycemia and diabetes on methylglyoxal and its detoxification pathways
19. Glycated protein update: Implications of recent studies, including the diabetes control and complications trial
20. Formation of glycine and aminoacetone from L-threonine by rat liver mitochondria
21. Glycation products and the pathogenesis of diabetic complications
22. Glycation and diabetic complications
23. Negative consequences of glycation
24. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
25. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging
26. Evaluation of glycosylated hemoglobin in diabetic patients
27. The glycosylation of hemoglobin: Relevance to diabetes mellitus
28. Reaction of monosaccharides with proteins. Possible evolutionary significances
29. Clinical validation of a second-generation fructosamine assay
30. Correlation of serum fructosamine activity in type I diabetic children
31. Validity of serum fructosamine as index of short-term glycemic control in diabetic outpatients
32. Clinical evaluation of serum fructosamine in monitoring elderly outpatient diabetics
33. Protein crosslinking by the Maillard reaction: Dicarbonyl-derived imidazolium crosslinks in aging and diabetes
34. Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription
35. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy
36. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: A placebo-controlled dose-comparison study
37. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: The influence of hypoalbuminaemia and hypergammaglobulinaemia
38. Interference with glycated hemoglobin by hemoglobin F may be greater than is generally assumed
39. Effect of vitamin C on glycosylation of proteins
40. Clustering of long-term complications in families with diabetes control and complications trial
41. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
42. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial
43. Retinopathy and nephropathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
44. Role of carbonyl stress in aging and age-related diseases
45. Assessment of past glycemic control. Measure fructosamine, hemoglobin A1, or both?
46. Formation of pentosidine during nonenzymatic browning of proteins by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo
47. Accumulation of Maillard reaction products in skin collagen in diabetes and aging
48. High 3-deoxyglucosone (3-Da) concentration in malformed rat embryos in vitro
49. Effects of hemoglobin C and S traits on seven glycohemoglobin methods
50. The presence of 2-keto-3-deoxygluconic acid and oxoaldehyde dehydrogenase activity in human erythrocytes
51. Non-enzymatic acetylation of human hemoglobins
52. Generation and characterization of a monoclonal antibody against AGES that induce endothelial dysfunction
53. Multicenter evaluation of Tosoh glycohemoglobin analyzer
54. Monitoring glycemia in diabetes: Short-term assessment
55. Tests of glycemia in diabetes
56. Glycated hemoglobin: Methodologies and clinical applications
57. Glycated hemoglobin estimation in the 1990s: A review of assay methods and clinical interpretation
58. Histones from diabetic rats contain increased levels of advanced glycation end products
59. Comparative evaluation of three assay systems for automated determination of hemoglobin A1c
60. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations
61. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
62. Formation of three-carbon sugar fragments at an early stage of the browing reaction of sugar with amines or amino acids
63. Detection and identification of protein-bound imidazolone resulting from the reaction of arginine residues and methylglyoxal
64. The reaction of some dicarbonyl sugars with aminoguanidine
65. Assay of serum fructosamine that minimizes standardization and matrix problems: Use to assess components of biological variation
66. Nonenzymatic glycosylation of albumin in vivo: Identification of multiple glycosylated sites
67. ADP-ribose in glycation and glycoxidation reactions
68. Fructosamine: A new approach to the estimation of serum glycosylprotein: An index of diabetic control
69. Biological variation of glycated hemoglobin
70. Increased fetal hemoglobin in insulin-treated diabetes mellitus contributes to the imprecision of glycohemoglobin measurements
71. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: Evidence for intermediate stages of the Maillard reaction in vivo
72. Enzyme catalysis: Not different, just better
73. A new colorimetric method for the determination of fructosamine
74. New hemoglobin in normal adult blood
75. Metabolism of fructose-3-phosphate in the diabetic rat lens
76. Production and metabolism of 3-deoxyglucosone in humans
77. New aspects of the Maillard reaction in foods and in the human body
78. Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay
79. Modification of plasma protein by methylglyoxal under physiological conditions: Prevention by aminoguanidine and arginine
80. Binding and modification of proteins by methylglyoxal under physiological conditions: A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin
81. Action des acides amines sur les sucres: Formation des melanoidines par vole methodique
82. Hemoglobin-AGE: A circulating marker of advanced glycosylation
83. Beta-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: Relation with fructosamine and mean erythrocyte age
84. Glycosylated minor components of human adult hemoglobin: Purification, identification, and partial structural analysis
85. The assay of methylglyoxal in biological systems by derivatization with 1, 2-diamino-4,5-dimethoxybenzene
86. Fluorimetric assay of D-lactate
87. Advanced glycation end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rat
88. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline
89. The role of the maillard reaction in the food industry
90. The Maillard reaction in aging, diabetes and nutrition
91. Plasma protein glycation as measured by fructosamine assay
92. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with noninsulin-dependent diabetes mellitus: The Verona Diabetes Study
93. Pyrraline ether crosslinks as a basis for protein crosslinking by the advanced Maillard reaction in aging and diabetes
94. Protein cross-linking by the Maillard reaction: Isolation, characterization, and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal
95. States of amino acid residues in proteins, XIV. Glyoxal as a reagent for discrimination of arginine residues
96. Effect of aspirin on determinations of glycosylated hemoglobin
97. The clinical information value of the glycosylated hemoglobin assay
98. Utility of serum fructosamine as a measure of glycemia in young and old diabetic and non-diabetic subjects
99. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
100. Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: Specific in vivo determination of inter-mediates in advanced Maillard reaction
101. Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines
102. A clinical approach for the diagnosis of diabetes mellitus: An analysis using glycosylated hemoglobin levels
103. The formation of methylglyoxal from triose phosphates: Investigation using a specific assay for methylglyoxal
104. Chromatographic evidence for pyrraline formation during protein glycation in vitro and in vivo
105. An abnormal hemoglobin in red cells of diabetes
106. Isolation and characterization of a blue fluorophore from human eye lens crystallins: In vitro formation from Maillard reaction with ascorbate and ribose
107. A comparative study on proliferation, macromolecular synthesis, and energy metabolism of in-vitro grown Ehlrich ascites tumor cells in the presence of glucosone, galactosone and methylglyoxal
108. Mechanism for the formation of methylglyoxal from triosephosphates
109. Fructosamine compared with a glucose load as a screening test for gestational diabetes
110. Glycohemoglobin results in samples with hemoglobin C or S trait: A comparison of four test systems
111. 1c by an immunoassay method
112. "Glycated hemoglobin," not "glycosylated" or "glucosylated"
113. Reaction of metformin with dicarbonyl compounds: Possible implication in the inhibition of advanced glycation end product formation
114. 3-deoxyglucosone reductase: Tissue distribution and purification of three multiple forms of the kidney enzyme that are identical with dihydrodiol dehydrogenase, aldehyde reductase and aldose reductase
115. Clinical utility of nonenzymatically glycosylated blood proteins as an index of glucose control
116. Is serum fructosamine assay specific for determination of glycated serum protein?
117. Standardization of serum fructosamine assays
118. Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy
119. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
120. End-stage renal disease and diabetes catalyze the formation of pentose-derived crosslink from aging human collagen
121. Structure elucidation of a senescence cross-link from human extracellular matrix
122. The relationship between serum fructosamine and albumin
123. Sites of nonenzymatic glycosylation of human hemoglobin A
124. Suppression of cell-cycle progression during the S-phase of rat fibroblasts by 3-deoxyglucosone, a Maillard reaction intermediate
125. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
126. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced diabetic rat
127. Glycation mediated lens crystallin aggregation and cross-linking by various sugars and sugar phosphates
128. 31P NMR evidence of an activated hexosemonophosphate shunt in hyperglycemic rat lenses in vivo
129. The response of GHb to stepwise plasma glucose change over time in diabetic patients
130. Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression
131. Effect of metformin on advanced glycation end product formation and peripheral nerve function in streptozotocin-induced diabetic rats
132. The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life
133. Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification - A role in pathogenesis and antiproliferative chemotherapy
134. Negative association between erythrocyte reduced glutathione concentration and diabetic complications
135. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes
136. Hemoglobin components in patients with diabetes mellitus
137. 1c, and fructosamine on diabetes screening
138. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
139. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
140. In vivo glycation of bovine lens crystallins
141. Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications
142. Influence of variations in albumin or total-protein concentration on serum fructosamine concentration
143. Vascular pharmacology of Metformin and the vascular effects of Metformin: Clinical assessment
144. 3-deoxyfructose concentrations are increased in human plasma and urine in diabetes
145. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods
146. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay
147. Increase in 3-deoxyglucasone levels in diabetic rat plasma
148. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia
149. Neurotoxicity of advanced glycosylation end products during focal stroke and neuroprotective effects of aminoguanidine
150. Formation of reactive intermediates from Amadori compounds under physiological conditions